Form 8-K · Current Report · Filed 2025-08-05
Halozyme Therapeutics Raises 2025 Financial Guidance and Reports Strong Q2 2025 Results
Halozyme Therapeutics, Inc. announced strong financial results for the second quarter of 2025, with a 41% increase in total revenue to $326 million and a 65% increase in royalty revenue to $206 million. The company also raised its 2025 financial guidance, projecting total revenue growth of 26% to 33% year-over-year, adjusted EBITDA growth of 37% to 45%, and non-GAAP diluted EPS growth of 42% to 51%. Additionally, Halozyme initiated a third $250 million share repurchase tranche under its $750 million authorized plan. These results reflect the strong performance of the company's blockbuster therapies and its industry-leading ENHANZE drug delivery technology.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-25-000033
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$59.99
Next session
+3.9%
Since filing
+83.8%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Exhibits (1)
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.